Abstract 4528
Background
Triple negative breast cancer carries a poor prognosis. Cytotoxic chemotherapy (chemo) is the standard of care. Recent data demonstrate that immunotherapy and anti-body drug conjugate based therapy can improve outcomes. Nevertheless survival remains poor. This SLR and MA was performed to assess the efficacy of current treatments for 2 nd line (2L) mTNBC.
Methods
EMBASE, MEDLINE, Cochrane databases were systematically searched from database inception to December 2018 for relevant studies of mTNBC with any systemic therapies in metastatic disease. Relevant congresses proceedings since 2016 and ClinicalTrials.gov were also searched. This SLR followed PRISMA guidelines with scope defined in terms of PICOS criteria (Population, Intervention, Comparators, Outcomes and Study design). Weighted averages (WA) for outcomes by treatment arm and line of therapy (LOT) were calculated. In addition, MA of overall response rate (ORR) among patients receiving single agent chemo (single chemo) as 2L and first line or later (1L+) was carried out using random-effects modeling for ORR.
Results
44 original studies were selected: 22 with 1L+, 7 with 2L, 15 with 2L or later (2L+). WAs of outcomes are presented in the Table. WAs of ORR for single chemo were less than ORR for combination chemo or chemo & biologics. No treatment showed consistently better survival over other treatments across all 3 groupings. MA of ORR in patients receiving single chemo as 2L and 1L+ were 11.9% (95% CI: 4.6, 20.8) and 15.6% (95% CI: 8.8-32.9), respectively. Table. Weighted Averages of Clinical Outcomes by Treatment and Line of Therapy.Table:
360P
Treatment | Line of Therapy | Overall Response Rate (%) | Progression Free Survival (median months) | Overall Survival (median months) |
---|---|---|---|---|
Single agent chemotherapy | 1L+ | 14.6 | 2.3 | 10.8 |
2L | 14.3 | 2.4 | 12.6 | |
2L+ | - | 3.1 | 12.3 | |
Combination chemotherapy | 1L+ | 29.7 | 4.4 | 10.5 |
2L | 31.0 | 4.1 | 10.0 | |
2L+ | - | 2.9 | 8.1 | |
Chemotherapy & Biologics | 1L+ | 22.6 | 2.9 | 10.6 |
2L | 35.8 | 5.6 | 17.9 | |
2L+ | 21.2 | 3.5 | 10.7 |
Conclusions
There is no clear standard of care in 2L TNBC. Response rates are low for single chemo and although response rates improve with combination therapies, no treatment regimen has demonstrated definitive improvement in outcomes. These results reinforce the need for new treatment strategies for mTNBC after 1L.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Purple Squirrel Economics.
Funding
Seattle Genetics, Inc.
Disclosure
P.A. Kaufman: Full / Part-time employment: Seattle Genetics, Inc. J. Feliciano: Full / Part-time employment: Seattle Genetics, Inc. P. Garfin: Full / Part-time employment: Seattle Genetics, Inc. L. Brown: Full / Part-time employment: Seattle Genetics, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract